SCHEDULE: Cabaletta Bio Stake Grows to 5.95% by Cormorant Asset Management

Cabaletta Bio, Inc. has disclosed that Cormorant Asset Management, LP, along with Bihua Chen, now beneficially owns 5.95% of the company's common stock, primarily through the exercise of warrants.

Summary

• Cabaletta Bio, Inc. is the subject of a Schedule 13G filing.
• Cormorant Asset Management, LP and Bihua Chen are the reporting persons.
• They collectively beneficially own 10,000,000 shares of common stock, representing 5.95% of the class.
• This ownership includes 5,000,000 shares of common stock and warrants to purchase an additional 5,000,000 shares.
• The percentage is calculated based on 163,054,796 shares outstanding as of May 7, 2026, as reported in the company's Q1 2026 10-Q.
• Cormorant Asset Management, LP is an investment adviser to Cormorant Funds.
• Bihua Chen is associated with the reporting persons and the Cormorant Funds.
• The filing is an amendment (Amendment No. 4) and was filed on 08/14/2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not overwhelming stake in the company by an investment manager, without immediate strong signals for major price movement.

Positives

• Increased institutional ownership by a known investment manager (Cabaletta Bio).
• The reporting persons hold a significant stake of 5.95%, indicating confidence in the company's prospects.
• The ownership is structured to include both direct shares and warrants, suggesting a strategic investment approach.

Negatives

• The filing does not contain specific financial performance data or operational updates, focusing solely on ownership.
• The large number of warrants could represent future dilution if exercised, though this is standard for warrant agreements.

Risks

• Potential for future share price volatility if Cormorant Asset Management decides to increase or decrease its stake significantly.
• The exercise of warrants could lead to dilution of existing shareholders' equity if not managed carefully by the company.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Cabaletta Bio, Inc. It solely reports on the ownership stake of Cormorant Asset Management, LP and Bihua Chen.

Management Comments

• The filing should not be construed as an admission that any of the reporting persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein.
• The Cormorant Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares reported herein.
• Cormorant Global Healthcare Master Fund, LP, a Cormorant Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the shares.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors increasing or establishing significant stakes in publicly traded companies. This filing indicates Cormorant Asset Management's continued interest in the biotechnology sector, specifically in Cabaletta Bio, Inc.

Stakeholder Impact

• Shareholders: May see increased trading volume and potential price fluctuations due to the significant stake held by an institutional investor.
• Company Management: May engage with Cormorant Asset Management regarding their investment strategy and company outlook.

Next Steps

• Monitor future filings from Cormorant Asset Management, LP for any changes in their stake.
• Observe Cabaletta Bio, Inc.'s performance and strategic developments that may influence the reporting persons' investment decisions.

Key Dates

Keywords

Cabaletta Bio, Cormorant Asset Management, Schedule 13G, Beneficial Ownership, Warrants, Institutional Investor, Common Stock, SEC Filing